Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Syndax Pharmaceuticals Inc (SNDX)
NASDAQ:SNDX
RESEARCH TOOLSreports
Holding SNDX?
Track your performance easily
SNDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$12.06 - $25.34
Previous CloseN/A
Volume201.89K
Average Volume (3M)2.49M
Market Cap
$1.11B
Enterprise Value$1.26B
Total Cash (Recent Filing)$105.33M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Mar 05, 2025EPS Estimate
-0.85Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.63
Shares Outstanding85,357,670
10 Day Avg. Volume1,808,952
30 Day Avg. Volume2,491,375
Standard Deviation0.16
R-Squared0.08
Alpha0.00861
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)69.35
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue78.49
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.29
Forecast
1Y Price Target
$36.82Price Target Upside181.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Syndax Pharmaceuticals News
PremiumCompany Announcements
Syndax Pharmaceuticals Restructures Leadership Team
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyThe BEAT study demonstrates strong performance with a 100% overall response rate and a 95% complete remission rate, indicating high efficacy of the treatment.
Market PositionSyndax is already first to market in r/r KMT2Ar acute leukemias and will likely be first to market in NPM1m, historically providing an advantage in market share.
Regulatory ApprovalRevuforj received FDA approval for the treatment of adult and pediatric patients one year and older with r/r acute leukemia with a KMT2A translocation.
Bears Say
Competitive PositioningThere is increased uncertainty concerning revumenib's competitiveness, prompting a cautious outlook ahead of its pivotal readout.
Safety ConcernsSafety remains a concern, with skepticism over the protocol's potential due to questions over baseline demographics and concerns over myelosuppressive related DLTs.
Sales ForecastsSales forecasts for axatilimab are being lowered due to its IV form being seen as a major drawback by prescribers.
---
Ownership Overview
5.98% Insiders
18.41% Mutual Funds
2.42% Other Institutional Investors
59.20% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SNDX FAQ
What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?
Syndax Pharmaceuticals Inc lowest stock price was $12.06 and its highest was $25.34 in the past 12 months.
What is Syndax Pharmaceuticals Inc’s market cap?
Syndax Pharmaceuticals Inc’s market cap is $1.11B.
When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?
Syndax Pharmaceuticals Inc’s upcoming earnings report date is Mar 05, 2025 which is in 46 days.
How were Syndax Pharmaceuticals Inc’s earnings last quarter?
Syndax Pharmaceuticals Inc released its earnings results on Nov 05, 2024. The company reported -$0.98 earnings per share for the quarter, beating the consensus estimate of -$1.07 by $0.09.
Is Syndax Pharmaceuticals Inc overvalued?
According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued.
Does Syndax Pharmaceuticals Inc pay dividends?
Syndax Pharmaceuticals Inc does not currently pay dividends.
What is Syndax Pharmaceuticals Inc’s EPS estimate?
Syndax Pharmaceuticals Inc’s EPS estimate is -0.85.
How many shares outstanding does Syndax Pharmaceuticals Inc have?
Syndax Pharmaceuticals Inc has 85,357,670 shares outstanding.
What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?
Syndax Pharmaceuticals Inc reported an EPS of -$0.98 in its last earnings report, beating expectations of -$1.07. Following the earnings report the stock price went up 8.431%.
Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in SNDX
---
Syndax Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.82 (181.50% Upside)
$36.82 (181.50% Upside)
Blogger Sentiment
Bullish
SNDX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 693.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-39.58%
12-Months-Change
Fundamentals
Return on Equity
-81.88%
Trailing 12-Months
Asset Growth
6.66%
Trailing 12-Months
Company Description
Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
---
SNDX Company Deck
---
SNDX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong positive trajectory for Syndax, highlighted by the FDA approval of Niktimvo and significant financial backing through the Royalty Pharma agreement. While the delay in the PDUFA date for Revumenib was a minor setback, the overall sentiment remains optimistic with multiple anticipated approvals and a robust financial position.Read More>---
SNDX Stock 12 Month Forecast
Average Price Target
$36.82
▲(181.50% Upside)
Technical Analysis
Best Analysts Covering SNDX
1 Year
1 Year Success Rate
10/17 ratings generated profit
1 Year Average Return
+25.56%
reiterated a buy rating 2 months ago
Copying Chris Shibutani's trades and holding each position for 1 Year would result in 58.82% of your transactions generating a profit, with an average return of +25.56% per trade.
---